179 related articles for article (PubMed ID: 1855772)
1. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells.
Suzuki Y; Ichihara T; Nakao A; Sakamoto J; Takagi H; Nagura H
Hepatogastroenterology; 1988 Jun; 35(3):128-35. PubMed ID: 3042577
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
Safi F; Roscher R; Beger HG
Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
[TBL] [Abstract][Full Text] [Related]
6. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
7. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of the ampulla of Vater: expression of cancer-associated antigens inversely correlated with prognosis.
Kamisawa T; Fukayama M; Koike M; Tabata I; Egawa N; Isawa T; Okamoto A; Hayashi Y
Am J Gastroenterol; 1988 Oct; 83(10):1118-23. PubMed ID: 3048082
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
10. [Basic and clinical evaluation of measurement of pancreatic cancer associated antigen, SPan-1].
Chung YS; Nakata B; Tanaka H; Kubo T; Satake K; Sowa M; Umeyama K
Nihon Geka Gakkai Zasshi; 1990 Feb; 91(2):228-33. PubMed ID: 2325607
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of pancreatic oncofetal antigen, pancreatic cancer associated antigen assay as tumor markers].
Shimano T; Morimoto H; Saito M; Mori T
Nihon Rinsho; 1990 Feb; 48 Suppl():917-9. PubMed ID: 2192174
[No Abstract] [Full Text] [Related]
13. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
[TBL] [Abstract][Full Text] [Related]
15. [Pancreatic oncofetal antigen (POA) and carcinoma of the pancreas].
Homma T; Oguchi H; Kawa S; Nagata A; Furuta S
Gan No Rinsho; 1984 May; 30(6 Suppl):558-62. PubMed ID: 6205174
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
Wang JY; Chen FZ; Yang YZ
Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
[TBL] [Abstract][Full Text] [Related]
18. [Pancreatic cancer-associated new carbohydrate antigen].
Yuan M
Zhonghua Zhong Liu Za Zhi; 1987 May; 9(3):183-6, 11. PubMed ID: 2452061
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibody SPan-1 in the diagnosis of exocrine pancreatic adenocarcinoma].
Frena A; Mazziotti A; La Guardia G; Martin F
Chir Ital; 2000; 52(4):369-77. PubMed ID: 11190527
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
